Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.

Anderson, T D; Hayes, T J; Gately, M K; Bontempo, J M; Stern, L L; Truitt, G A

Anderson, T D; Hayes, T J; Gately, M K; Bontempo, J M; Stern, L L; Truitt, G A.

Affiliation

Anderson TD; Department of Toxicology and Pathology, Hoffmann-La Roche Inc., Nutley, New Jersey.

Lab Invest ; 59(5): 598-612, 1988 Nov.

Article in En | MEDLINE | ID: mdl-3263543

Subject(s)

G(M1) Ganglioside; Interleukin-2/toxicity; Lymphocyte Activation; Lymphocytes/physiology; Adenocarcinoma/therapy; Animals; Antibodies, Monoclonal/administration & dosage; Capillary Permeability; Colonic Neoplasms/therapy; Glycosphingolipids/immunology; Hyperplasia; Immunotherapy; Killer Cells, Natural/immunology; Liver Diseases/etiology; Mice; Pleural Effusion/etiology; Pulmonary Edema/etiology; Recombinant Proteins; Spleen/pathology

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Lymphocyte Activation / Lymphocytes / Interleukin-2 / G(M1) Ganglioside Type of study: Etiology_studies / Prognostic_studies Limits: Animals Language: En Year: 1988 Type: Article

Search on Google

XML

PubMed Links